Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication TRILEPTAL is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. FDA label
oxcarbazepine · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| oxcarbazepine | DRUG | - |
INCLUSION CRITERIA: To enter this study, patients must: * Have a diagnosis of partial seizures * Have 2-30 seizures per week while on a stable dose of one anti-epileptic drug or be a patient recently diagnosed with partial seizures and currently receiving no seizure medication * Be willing to be ho...
Top 9 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. | XENE | 4 | PHASE3 | Azetukalner |
| Praxis Precision Medicines, Inc. | PRAX | 5 | PHASE3 | Vormatrigine, Elsunersen |
| Rapport Therapeutics, Inc. | RAPP | 3 | PHASE3 | RAP-219 |
| Supernus Pharmaceuticals, Inc. | SUPN | 4 | PHASE2 | SPN-817, Treatment B, BIS-001ER |
| Biohaven Ltd. | BHVN | 3 | PHASE2 | BHV-7000 |
| Harmony Biosciences Holdings, Inc. | HRMY | 1 | PHASE3 | Clemizole |
| Jazz Pharmaceuticals Public Limited Company | JAZZ | 3 | PHASE1 | CBD-OS, Epidiolex |
| Bright Minds Biosciences Inc. | DRUG | 1 | PHASE2 | BMB-101 |
| uniQure N.V. | QURE | 1 | PHASE1 | AMT-260 |
Oxcarbazepine is used for epilepsy. It is a small molecule developed by Novartis AG for the neurology therapeutic area. The clinical program has studied it in epilepsy, including partial epilepsies, in pediatric patients. Two Phase 3 trials in epilepsy have been completed, enrolling a total of 226 participants.
Oxcarbazepine targets sodium channel proteins SCN1A, SCN5A, SCN4A, SCN7A, SCN2A, and SCN9A. It acts as a blocker of these targets. This target class is consistent with its development as a small molecule for epilepsy under Novartis AG.
Oxcarbazepine is developed by Novartis AG, which trades under the ticker NVS. Novartis is the company associated with the clinical development program for oxcarbazepine in epilepsy.
Oxcarbazepine is in Phase 3 clinical development for epilepsy. Two Phase 3 trials have been completed, and no trials are currently active. The program has enrolled 226 participants in total across those completed studies.
Oxcarbazepine has been studied in two completed Phase 3 pediatric epilepsy trials: NCT00050947, which enrolled 94 participants, and NCT00050934, which enrolled 132 participants and included partial epilepsies. Both trials were conducted in the United States, Brazil, Germany, and Mexico, and enrolled participants from one month of age.